

**AGO Kommission Mamma:**  
**Formblatt zur Offenlegung von Interessenskonflikten**  
*Bitte bis 22.01.2019 Original ausgefüllt (Name lesbar auf beiden Seiten!) und unterschrieben an:*

**Prof. Dr. med. Nadia Harbeck**

per mail: [nadia.harbeck@med.uni-muenchen.de](mailto:nadia.harbeck@med.uni-muenchen.de)

oder FAX: 089 / 4400 - 7 7582

oder Post: Brustzentrum der Universität München, Marchioninstr. 15, 81377 München

Name: \_\_\_\_\_

Funktion: \_\_\_\_\_

Arbeitgeber: \_\_\_\_\_

Öffentlicher Dienst: ja

Prof. Dr. med. Volker Hanf

Chefarzt Frauenklinik

Jakob-Henle-Str. 1

90760 Fürth/Bay.

Tel.: 09 11 / 75 00 - 13 01

Mögliche Interessenskonflikte:

Hiermit lege ich folgende Zusammenarbeiten / Verbindungen mit Industrieunternehmen / privaten oder öffentliche Geldgebern mit kommerziellen Interessen im Bereich Krebstherapie / Krebsforschung offen. Diese Offenlegung betrifft ebenfalls Personen mit denen ich ein gemeinsames Einkommen erwirtschaftete sowie erwachsene Kinder, falls durch deren berufliche Tätigkeit ein Interessenskonflikt besteht.

Zeitraum, für den die Offenlegung gilt: **1. Jan. 2018 bis 31. Dez. 2018**

Bereiche (dann analog zum JCO mit **jeweils** Nennung der Firma und Kategorie für den Zuwendungsbetrag):

**1) Anstellungsverhältnis / Aufsichtsratsmitgliedschaft:**

Klinikum Fürth, keine Konflikte

**2) Beratertätigkeit:**

Ad-Board: Astra-Zeneca (A); Novartis (A)

**3) Aktienbesitz** (mit der Ausnahme von Fondsanteilen, deren Investmenttätigkeit sich der direkten Kontrolle entzieht):

∅

Name: HANF

4) Honorare für Vorträge etc.:

AstraZeneca (A); Novartis (A)

5) Forschungsförderung:

∅

6) Expertengutachten:

∅

7) sonstige Zuwendungen:

∅

Folgende Kategorien für Zuwendungsbeträge sollten hierbei unterschieden werden:


- A. < 10,000 €
- B. 10,000 - 99,999 €
- C. > 100,000 €

Hiermit versichere ich, dass die o.g. Angaben wahrheitsgemäß nach bestem Wissen und Gewissen unter Berücksichtigung der Grundsätze zur Offenlegung von Interessenskonflikten AGO Kommission Mamma (Version vom [02.02.05]) gemacht habe.

Ort, Datum:

Freiburg 26.11.2019

mit Ihrer Unterschrift:

Gez: 

Conflict of Interest

Prof. E. Solomayer

Roche, Amgen, Celgen, Tesaro, Astra Zeneca, Pfizer, Storz, Erbe, Gedeon Richter, Eisai,  
Medac, MSD, Vifor, Teva, Ethikon,

*Solomayer*, 26.3.2019

## **Conflict of Interest**

M. Schmidt received honoraria for speaker or consultancy role from AMGEN, AstraZeneca, Eisai, Lilly, Myelo Therapeutics, Novartis, Pantarhei Bioscience, Pfizer, and Roche. He received research funding from AstraZeneca, BioNTech, Eisai, Genentech, Myelo Therapeutics, Novartis, Pantarhei Bioscience, Pierre-Fabre, and Roche. He received travel reimbursement from Pfizer and Roche.

## ICMJE Form for Disclosure of Potential Conflicts of Interest

---

### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

#### 1. Identifying information.

#### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name) Andreas      2. Surname (Last Name) Schneeweiss      3. Date 23-January-2019

4. Are you the corresponding author?     Yes     No      Corresponding Author's Name  
Sibylle Loibl

5. Manuscript Title  
A phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study

6. Manuscript Identifying Number (if you know it)  
\_\_\_\_\_

### Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?     Yes     No

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest?     Yes     No

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Celgene	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Research Grant
Roche	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Research Grant
AbbVie	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Research Grant
Molecular Partner	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Research Grant
Roche	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Expert testimony
AstraZeneca	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Expert testimony
Celgene	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Travel expenses
Roche	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Travel expenses

## ICMJE Form for Disclosure of Potential Conflicts of Interest

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Roche	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria
Celgene	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria
Pfizer	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria
AstraZeneca	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria
Novartis	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria
MSD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria
Tesaro	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria
Lilly	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria

### Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  Yes  No

### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
- No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

## ICMJE Form for Disclosure of Potential Conflicts of Interest

---

### Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Schneeweiss reports grants from Celgene, grants from Roche, grants from AbbVie, grants from Molecular Partner, personal fees from Roche, personal fees from AstraZeneca, personal fees from Celgene, personal fees from Roche, personal fees from Roche, personal fees from Celgene, personal fees from Pfizer, personal fees from AstraZeneca, personal fees from Novartis, personal fees from MSD, personal fees from Tesaro, personal fees from Lilly, outside the submitted work; .

### Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.



**Interessenskonflikte (COI):**

Honorare für Vorträge und/oder Beratertätigkeit in den letzten drei Jahren:

Amgen AG, AstraZeneca GmbH, Lilly AG, Hexal AG, MSD GmbH, Novartis AG, Pfizer GmbH, Roche AG, OnkoZert GmbH, Eickeler Kongressorganisation.

**Prof. Dr. med. Florian Schütz**  
Stellvertretender Klinikdirektor / Leiter Brustzentrum  
Universitäts-Frauenklinik  
Im Neuenheimer Feld 440, 69120 Heidelberg  
Tel.: +49 (0)6221 56-37688  
Tel. Sekr.: +49 (0)6221 56-7906  
Fax: +49 (0)6221 56-5712  
E-Mail: florian.schuetz@med.uni-heidelberg.de

**Ditsch, Nina Prof. Dr.**

---

**Von:** Stickeler, Elmar <estickeler@ukaachen.de>  
**Gesendet:** Sonntag, 24. März 2019 16:03  
**An:** Ditsch, Nina Prof. Dr.  
**Betreff:** Breast Care AGO Update  
**Anlagen:** scanned20190324155614.pdf


Liebe Frau Dietsch,

anbei mein Submission Statement zu Volkmar Müllers und meinem Teil: Spezielle Situationen für den EBC Part.

Mein formloses COI Statement:


E.S. declares that he has no conflict of interest.

Herzliche Grüße und vielen Dank für Ihre Mühe,

 Elmar Stickeler

Univ.-Prof. Dr. med. Elmar Stickeler  
Direktor der Klinik für Gynäkologie und Geburtsmedizin Universitätsklinikum Aachen (UKA) Pauwelsstraße 30 D  
52074 Aachen  
Fon.: ++ 49 241 80 88 400  
Fax: ++ 49 241 80 82 476  
estickeler@ukaachen.de  
Anstalt des öffentlichen Rechts  
Sitz Aachen  
Vorstandsvorsitzender: Herr Prof. Dr. Thomas H. Ittel Kaufmännischer Direktor: Herr Peter Asché

-----Ursprüngliche Nachricht-----

 Von: Stickeler, Elmar <estickeler@ukaachen.de>  
Gesendet: Sonntag, 24. März 2019 15:56  
An: Stickeler, Elmar <estickeler@ukaachen.de>  
Betreff: KYOcontrol Scanauftrag von Gerät <MFP\_031>

## Ditsch, Nina Prof. Dr.

---

**Von:** Thill, Marc <Marc.Thill@fdk.info>  
**Gesendet:** Sonntag, 31. März 2019 20:37  
**An:** Ditsch, Nina Prof. Dr.  
**Betreff:** AW:

...oder schickst Du die COIs zum Verlag?

Anbei meine COIs für Dich, obwohl ich Sie ja an mein Manuskript hängen werde.

**Consulting or advisory role:**

Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Genomic Health, Hexal, Lilly, MSD, Myriad, Neodynamics, Norgine, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical, Somatex, SurgicEye, Teva

**Speaker honoraria:**

Amgen, AstraZeneca, Aurikamed, Celgene, Eisai, Genomic Health, Hexal, Lilly, Myriad, Neodynamics, Novartis, OnkoLive, OmniaMed, Pfizer, pfm Medical, Roche, RTI Surgical, SurgicEye, Teva

**Manuscript support:**

Amgen, Roche, Celgene

**Trial Funding:**

Genomic Health

LG

M

*Submission Statement  
direkt an Verlag*

PD Dr. med. Marc Thill

Chefarzt

Klinik für Gynäkologie und Gynäkologische Onkologie Interdisziplinäres Brustzentrum (DKG/DGS) Gynäkologisches Krebszentrum (DKG) Gynäkologische Dysplasie-Einheit (DKG) Zertifiziertes Endometriosezentrum (SEF/EEL) Kooperatives Sarkomzentrum (DKG) AGAPLESION MARKUS KRANKENHAUS

T (069) 95 33 - 22 28

M (069) 95 33 - 66 382

F (069) 95 33 - 27 33

marc.thill@fdk.info

AGAPLESION FRANKFURTER DIAKONIE KLINIKEN gemeinnützige GmbH, Ginnheimer Landstraße 94, 60487 Frankfurt am Main

Büroadresse: AGAPLESION MARKUS KRANKENHAUS, Wilhelm-Epstein-Straße 4, 60431 Frankfurt am Main

Rechnungsadresse: AGAPLESION FRANKFURTER DIAKONIE KLINIKEN gemeinnützige GmbH, Wilhelm-Epstein-Straße 4, 60431 Frankfurt am Main

Besuchen Sie unsere Website: [www.fdk.info](http://www.fdk.info)

Geschäftsführer: Michael Keller (Sprecher), Jürgen Schäfer, Gesellschafterversammlung: Dr. Lothar Elsner (Vors.) Sitz der Gesellschaft und Registergericht: Frankfurt am Main, HRB 12146

-----  
Marc Thill, M.D., Ph.D  
Head of Department

Conflicts of interest:

Prof. Dr. med. Michael Untch has received honoraria for Advisory Board activities and/or oral presentations, travel grants, all paid to his institution from

Abbvie

Amgen GmbH München

Astra Zeneca

BMS

Celgene GmbH München

Daiichi Sankyo

Eisai GmbH München

Janssen Cilag

Johnson & Johnson

Lilly Deutschland

Lilly Int.

MSD Merck

Mundipharma

Myriad Genetics GmbH Zürich

Odonate

Pfizer GmbH Berlin

PUMA Biotechnology

Riemser

Roche Pharma AG, Grenzach Wyhlen

Sanofi Aventis Deutschland GmbH

Sividon Diagnostics Köln

TEVA Pharmaceuticals Ind. Ltd. und . Berlin

Conflicts of interest:

Prof. Dr. med. Achim Wöckel has received honoraria for Advisory Board activities and/or oral presentations from

- Amgen
- AstraZeneca
- Aurikamed
- Celgene
- Eisai
- Lilly
- Novartis
- Pfizer
- Roche
- Tesaro

## Ditsch, Nina Prof. Dr.

---

**Von:** Prof. Dr. Frederik Wenz <frederik.wenz@uniklinik-freiburg.de>  
**Gesendet:** Mittwoch, 20. März 2019 10:11  
**An:** Achim.Rody@uksh.de  
**Cc:** Ditsch, Nina Prof. Dr.; Thill, Marc; Wilfried.Budach@med.uni-duesseldorf.de  
**Betreff:** Re: AW: Breast Care: AGO Update 2019

Hallo, habe inzwischen auch keinen COI mehr. Gruß Wenz

Mit besten Grüßen

Prof. Dr. Frederik Wenz  
Leitender Ärztlicher Direktor und  
Vorstandsvorsitzender

\*\*\*\*\*

UNIVERSITÄTSKLINIKUM FREIBURG  
Prof. Dr. Frederik Wenz  
Leitender Ärztlicher Direktor und  
Vorstandsvorsitzender

[Breisacher Straße 153, 79110 Freiburg](#)  
Telefon: +49 (0)761 270-18060  
Telefax: +49 (0)761 270-9618070  
[frederik.wenz@uniklinik-freiburg.de](mailto:frederik.wenz@uniklinik-freiburg.de)

[www.uniklinik-freiburg.de](http://www.uniklinik-freiburg.de)

Am 20.03.2019 um 10:09 schrieb "[Achim.Rody@uksh.de](mailto:Achim.Rody@uksh.de)" <[Achim.Rody@uksh.de](mailto:Achim.Rody@uksh.de)>:

Liebe Nina,

in Anlage übersende ich Dir den Part „Adjuvante Strahlentherapie“.  
In Bezug auf Strahlentherapie habe ich keinen COI.  
Submission Statement folgt separat.  
Bei Fragen, darfst Du Dich gerne an mich wenden.

Herzliche Grüße

Achim

---

**Von:** Ditsch, Nina Prof. Dr. [<mailto:Nina.Ditsch@med.uni-muenchen.de>]  
**Gesendet:** Mittwoch, 20. März 2019 09:45  
**An:** [ago.mamma@lists.uni-ulm.de](mailto:ago.mamma@lists.uni-ulm.de)  
**Cc:** [Marc.Thill@fdk.info](mailto:Marc.Thill@fdk.info)  
**Betreff:** Breast Care: AGO Update 2019

Liebe Autoren,

wir bedanken uns für die bereits zugesandten Artikel und bitten diejenigen, deren Artikel noch ausstehen, diese zu schicken – **bitte bis spätestens Sonntag Abend!!!**

Klinikum Esslingen GmbH · Postfach 10 07 53 · 73707 Esslingen

**Klinik Frauenheilkunde und Geburtshilfe**  
**Chefarzt: Professor Dr. Thorsten Kühn**

Interdisziplinäres Brustkrebszentrum  
Zentrum für gynäkologische Tumorerkrankungen  
Mutter-Kind-Zentrum  
Perinatalzentrum - Level 1

Tel. 0711 - 3103 3051

Fax 0711 - 3103 3052

[frauenklinik@klinikum-esslingen.de](mailto:frauenklinik@klinikum-esslingen.de)

[www.klinikum-esslingen.de](http://www.klinikum-esslingen.de)


21.03.2019



## **Erklärung über Interessenskonflikte für Zeitschrift „Breast Care“ ; Publikation der AGO Leitlinien**

Hiermit erkläre ich, daß ich in Zusammenhang mit dem Kapitel operative Therapie unter onkologischen Aspekten keine themenspezifischen Interessenskonflikte habe.

Im Jahr 2018 habe ich Vertragshonorare der Firmen Pfizer, Celgene, Novartis und Roche Pharma erhalten.

  
Prof. Dr. med. T. Kühn  
Chefarzt



This is a disclosure report of your financial relationships with for-profit health care companies. Please keep your disclosure current and visit [coi.asco.org](http://coi.asco.org) to make any updates or revisions.

*All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution*

#### **Employment**

No Relationships to Disclose

---

#### **Leadership**

No Relationships to Disclose

---

#### **Stock and Other Ownership Interests**

No Relationships to Disclose

---

#### **Honoraria**

No Relationships to Disclose

---

#### **Consulting or Advisory Role**

**Company:** Roche/Genentech

**Recipient:** You

**Company:** Genomic Health

**Recipient:** You

**Company:** Novartis

**Recipient:** You

**Company:** AstraZeneca

**Recipient:** You

**Company:** Amgen

**Recipient:** You

**Company:** Celgene

**Recipient:** You

**Company:** SOMATEX

**Recipient:** You

**Company:** Daiichi Sankyo

**Recipient:** You



**Company:** Puma Biotechnology

**Recipient:** You

**Company:** pfm medical

**Recipient:** You

**Company:** Pfizer

**Recipient:** You

**Company:** MSD Oncology

**Recipient:** You

---

**Speakers' Bureau**

No Relationships to Disclose

---

**Research Funding**

No Relationships to Disclose

---

**Patents, Royalties, Other Intellectual Property**

No Relationships to Disclose

---

**Expert Testimony**

No Relationships to Disclose

---

**Travel, Accommodations, Expenses**

**Company:** Roche

**Recipient:** You

**Company:** Daiichi Sankyo

**Recipient:** You

---

**Other Relationship**

No Relationships to Disclose

---

**Ditsch, Nina Prof. Dr.**

---

**Von:** Lux Michael Patrick <M.Lux@vincenz.de>  
**Gesendet:** Mittwoch, 20. März 2019 23:53  
**An:** Ditsch, Nina Prof. Dr.; Marc.Thill@fdk.info  
**Betreff:** AW: Breast Care: AGO Update 2019

Liebe Nina, lieber Marc,

hier noch meine COIs:

**M.P.L.** has participated on advisory boards for AstraZeneca, MSD, Novartis, Pfizer, Eisai, Genomic Health, Tesaro, Grünethal and Roche and has received honoraria for lectures from MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health, AstraZeneca, medac and Eisai.

Liebe Grüße  
Mike

---

**Von:** Lux, Michael (extern) [Michael.Lux@extern.uk-erlangen.de]  
**Gesendet:** Mittwoch, 20. März 2019 10:20  
**An:** Lux Michael Patrick  
**Betreff:** Fwd: Breast Care: AGO Update 2019

Von meinem iPhone gesendet

Anfang der weitergeleiteten Nachricht:

**Von:** "Ditsch, Nina Prof. Dr." <[Nina.Ditsch@med.uni-muenchen.de](mailto:Nina.Ditsch@med.uni-muenchen.de)>  
**Datum:** 20. März 2019 um 09:45:23 MEZ  
**An:** "[ago.mamma@lists.uni-ulm.de](mailto:ago.mamma@lists.uni-ulm.de)" <[ago.mamma@lists.uni-ulm.de](mailto:ago.mamma@lists.uni-ulm.de)>  
**Kopie:** "[Marc.Thill@fdk.info](mailto:Marc.Thill@fdk.info)" <[Marc.Thill@fdk.info](mailto:Marc.Thill@fdk.info)>  
**Betreff:** Breast Care: AGO Update 2019

Liebe Autoren,

wir bedanken uns für die bereits zugesandten Artikel und bitten diejenigen, deren Artikel noch ausstehen, diese zu schicken – **bitte bis spätestens Sonntag Abend!!!**  
Zusätzlich bitte an COI und Submission Statement denken (beides bitte mitschicken!!!)

1. **COI:** Alle Autoren müssen bei Abgabe des Artikels ein formloses COI-Statement abgeben, das mit abgedruckt wird. Es gibt hierzu keine Vorlage des Verlags.
2. **Submission Statement:** Es muss für jedes Manuskript von allen Autoren unterzeichnet werden. Bitte fügen Sie jeweils den Titel oben ein, damit die Unterschriften dem richtigen Manuskript zuzuordnen sind. Autoren, die bei beiden Manuskripten auf der Liste stehen, müssen auch **zweimal** unterschreiben.

**Deadline-Erweiterung bis 24.03.2019**

Viele Grüße von Marc und Nina

Conflicts of interest:

Prof. Dr. med. Diana Lüftner has received honoraria for Advisory Board activities and/or oral presentations from

- Amgen
- AstraZeneca
- Celgene
- Lilly
- Loreal
- MSD
- Mundipharma
- Mylan
- Novartis
- Pfizer
- Roche
- Teva
- Tesaro

## Ditsch, Nina Prof. Dr.

---

**Von:** WEISSMÜLLER\_FK\_STUDIENSEKRETARIAT  
<Christina.Weissmueller@KlinikumFrankfurt.de>  
**Gesendet:** Freitag, 22. März 2019 09:24  
**An:** Ditsch, Nina Prof. Dr.; Marc.Thill@fdk.info  
**Betreff:** AGO Update 2019 - Möbus/ Submission Statement und COI  
**Anlagen:** CCF\_000151.pdf

Liebe Frau Prof. Ditsch,  
lieber Herr PD Dr. Thill,

anbei erhalten Sie das Submission Statement für Breast Care von Prof. Möbus.  
Seine COIs sind folgende:  
Honorare: Amgen, Celgene, Roche, Myelotherapeutics, AstraZeneca  
Consulting/Advisory Role: Myelotherapeutics, Roche, Amgen.

Beste Grüße,  
C. Weißmüller

---

Christina Weißmüller  
Studienassistentin

Klinikum Frankfurt Höchst GmbH  
Klinik für Gynäkologie und Geburtshilfe  
Prof. Dr. med. Volker Möbus  
Gotenstraße 6-8, 65929 Frankfurt/M.  
Telefon: +49 (0)69 / 3106 3552  
Fax: +49 (0)69 / 300 599 46  
eMail: [christina.weissmueller@KlinikumFrankfurt.de](mailto:christina.weissmueller@KlinikumFrankfurt.de)  
[www.klinikumfrankfurt.de](http://www.klinikumfrankfurt.de)  
Ein Unternehmen der Kliniken Frankfurt-Main-Taunus GmbH

Klinikum Frankfurt Höchst GmbH | Gotenstraße 6-8 | 65929 Frankfurt a.M.  
Tel.: +49 69/3106-0 | Fax: +49 69/3106-3030 | [www.KlinikumFrankfurt.de](http://www.KlinikumFrankfurt.de)

Geschäftsführung: Martin Menger (Vors.) | Dr. Dorothea Dreizehnter  
Aufsichtsratsvorsitzender der Kliniken Frankfurt-Main-Taunus: Harald Schmidt

Sitz der Gesellschaft: Frankfurt am Main  
Amtsgericht Frankfurt am Main HRB 77741 | UST-IDNR.: DE 815 124 730  
Ein Unternehmen der Kliniken Frankfurt-Main-Taunus GmbH

Wichtiger Hinweis: Diese E-Mail enthält vertrauliche Informationen. Wenn Sie diese E-Mail irrtümlich erhalten haben, informieren Sie bitte sofort den Absender und vernichten Sie diese E-Mail inklusive Anlagen und aller Kopien.

Die Anfertigung unerlaubter Kopien, die Weitergabe der Informationen sowie die unbefugte Weitersendung sind nicht gestattet.

**Ditsch, Nina Prof. Dr.**

---

**Von:** Christoph Mundhenke <cmundhenke@hotmail.com>  
**Gesendet:** Samstag, 23. März 2019 17:20  
**An:** Ditsch, Nina Prof. Dr.; Thill, Marc  
**Betreff:** WG: Breast Care /COI  
**Anlagen:** IMG\_6304.JPG; ATT00001.txt

Liebe Frau Ditsch, lieber Marc,

ich habe keinen COI beim Thema "Nachsorge".

Eiin schönes Wochenende

LG Christoph Mundhenke

Prof. Dr. Christoph Mundhenke, M.A.  
Ltd. Oberarzt  
Frauenklinik, Universitätsklinikum Schleswig-Holstein, Kiel  
Arnold-Heller-Str. 3  
24105 Kiel  
Tel. 0431-500-21410

---

Von: Christoph Mundhenke <cmundhenke@hotmail.com>  
Gesendet: Samstag, 23. März 2019 16:36  
An: Christoph Mundhenke  
Betreff:

## Submission Statement


Article Title:

AGO Recommendations Early Breast Cancer

Every author must sign 1 copy of this Submission Statement with his/her original signature.

In signing the Submission Statement, the authors confirm that they have read and agreed to the full submission statement below, including that

- the submission is original and has not been previously published
- all permissions have been obtained
- the manuscript includes all the relevant statements and acknowledgements
- the copyright is transferred to S. Karger AG on acceptance

Printed Name:	E-Mail:	Signature:	Place and Date:
Müller-Schimpfle	mms@klinikumfrankfurt.de		Frankfurt/M. 24.07.19

Author holds a Royalty of Cook Company and


Please print and sign the form, and upload it during submission or fax or e-mail it to:

has received honoraria for oral presentations from

Fujifilm and  
Devicor

**S. Karger AG - Medical and Scientific Publishers**  
Editorial Office Breast Care  
Allschwilerstrasse 10  
CH-4009 Basel (Switzerland)  
Fax: +41 61 306 14 34  
E-Mail: brc@karger.com

Frankfurt, 24.7.19



COI – conflict of interest, PD Dr. Kerstin Rhiem

Honoraria for Advisory Boards and oral presentations

Astra Zeneca

Tesaro

**Ditsch, Nina Prof. Dr.**

---

**Von:** Achim.Rody@uksh.de  
**Gesendet:** Mittwoch, 20. März 2019 10:07  
**An:** Ditsch, Nina Prof. Dr.  
**Cc:** Thill, Marc; 'Prof. Dr. Frederik Wenz' (frederik.wenz@uniklinik-freiburg.de); Wilfried.Budach@med.uni-duesseldorf.de  
**Betreff:** AW: Breast Care: AGO Update 2019  
**Anlagen:** Adjuvant Radiotherapy Breast Care\_AR mod Budach.docx

Liebe Nina,

in Anlage übersende ich Dir den Part „Adjuvante Strahlentherapie“.

In Bezug auf Strahlentherapie habe ich keinen COI.

Submission Statement folgt separat.

Bei Fragen, darfst Du Dich gerne an mich wenden.

→ direkt an Verlag

Herzliche Grüße

Achim

---

**Von:** Ditsch, Nina Prof. Dr. [mailto:Nina.Ditsch@med.uni-muenchen.de]

**Gesendet:** Mittwoch, 20. März 2019 09:45

**An:** ago.mamma@lists.uni-ulm.de

**Cc:** Marc.Thill@fdk.info

**Betreff:** Breast Care: AGO Update 2019

Liebe Autoren,

wir bedanken uns für die bereits zugesandten Artikel und bitten diejenigen, deren Artikel noch ausstehen, diese zu schicken – bitte bis **spätestens Sonntag Abend!!!**

Zusätzlich bitte an COI und Submission Statement denken (beides bitte mitschicken!!!)

1. **COI:** Alle Autoren müssen bei Abgabe des Artikels ein formloses COI-Statement abgeben, das mit abgedruckt wird. Es gibt hierzu keine Vorlage des Verlags.
2. **Submission Statement:** Es muss für jedes Manuskript von allen Autoren unterzeichnet werden. Bitte fügen Sie jeweils den Titel oben ein, damit die Unterschriften dem richtigen Manuskript zuzuordnen sind. Autoren, die bei beiden Manuskripten auf der Liste stehen, müssen auch **zweimal** unterschreiben.

**Deadline-Erweiterung bis 24.03.2019**

Viele Grüße von Marc und Nina





**Conflict of Interest  
Disclosure Report**

Christine Solbach, MD, PhD  
Department of Gynecology and Obstetrics  
Goethe-University Hospital Frankfurt, Germany

This is a disclosure report of your financial relationships with for-profit health care companies. Please keep your disclosure current and visit [coi.asco.org](http://coi.asco.org) to make any updates or revisions

*All relationships are considered compensated Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution*

**Employment**

No Relationships to Disclose

---

**Leadership**

No Relationships to Disclose

---

**Stock and Other Ownership Interests**

No Relationships to Disclose

---

**Honoraria**

No Relationships to Disclose

---

**Consulting or Advisory Role**

**Company:** Olympus Europa

**Recipient:** You

---

**Travel, Accommodations, Expenses**

**Company:** ROCHE

**Recipient:** You

**Company:** Genomic Health

**Recipient:** You

**Company:** Novartis

**Recipient:** You

**Company:** AstraZeneca

**Recipient:** You

**Company:** Amgen

**Recipient:** You

**Company:** Celgene

**Recipient:** You

**Company:** Hexal

**Recipient:** You

**Company:** Daiichi Sankyo

**Recipient:** You

**Company:** Dialog Service GmbH

**Recipient:** You

**Company:** Lilly  
**Recipient:** You

**Company:** Pfizer  
**Recipient:** You

**Company:** MSD Oncology  
**Recipient:** You

**Company:** ESAI  
**Recipient:** You

**Company:** Gedon Richter  
**Recipient:** You

**Company:** Mylan  
**Recipient:** You

**Company:** TESARO  
**Recipient:** You

**Speakers' Bureau**  
No Relationships to Disclose

---

**Research Funding**  
No Relationships to Disclose

---

**Patents, Royalties, Other Intellectual Property**  
No Relationships to Disclose

---


**Expert Testimony**  
No Relationships to Disclose

---

**Other Relationship**  
No Relationships to Disclose

---

25th March 2019



**Submission Statement**

**Article Title:**

*adjuvante endokrine Therapie*

Every author must sign 1 copy of this Submission Statement with his/her original signature.

In signing the Submission Statement, the authors confirm that they have read and agreed to the full submission statement below, including that

- the submission is original and has not been previously published
- all permissions have been obtained
- the manuscript includes all the relevant statements and acknowledgements
- the copyright is transferred to S. Karger AG on acceptance

Printed Name:	E-Mail:	Signature:	Place and Date:
<i>Gerber</i>	<i>bernd.gerber@med.uni-rostock.de</i>	<i>B. Gerber</i>	<i>HRD 20.03.19</i>

*Es besteht kein Interessenkonflikt im Sinne der Empfehlungen des Int. Committee of Medical Journal Editors*

Please print and sign the form, and upload it during submission or fax or e-mail it to:

**S. Karger AG - Medical and Scientific Publishers**  
 Editorial Office *Breast Care*  
 Allschwilerstrasse 10  
 CH-4009 Basel (Switzerland)  
 Fax: +41 61 306 14 34  
 E-Mail: brc@karger.com

*B. Gerber*

**Ditsch, Nina Prof. Dr.**

---

**Von:** Jens.Huober@uniklinik-ulm.de  
**Gesendet:** Freitag, 22. März 2019 07:37  
**An:** Ditsch, Nina Prof. Dr.; Marc.Thill@fdk.info  
**Betreff:** AW: Breast Care: AGO Update 2019

Liebe Beide,  
Bzgl. der gynäkologischen Symptome habe ich keine COI. Ich nehme an, dass dies nur auf das Kapitel bezogen ist für das man steht.  
Das unterschriebene Statement kann ich erst am Montag senden, da ich seit Dienstag in Wien bin.  
Viele Grüße,  
Jens

---

**Von:** Ditsch, Nina Prof. Dr. [mailto:Nina.Ditsch@med.uni-muenchen.de]  
**Gesendet:** Mittwoch, 20. März 2019 09:45  
**An:** ago.mamma@lists.uni-ulm.de  
**Cc:** Marc.Thill@fdk.info  
**Betreff:** Breast Care: AGO Update 2019

Liebe Autoren,

wir bedanken uns für die bereits zugesandten Artikel und bitten diejenigen, deren Artikel noch ausstehen, diese zu schicken – **bitte bis spätestens Sonntag Abend!!!**  
Zusätzlich bitte an COI und Submission Statement denken (beides bitte mitschicken!!!)

1. **COI:** Alle Autoren müssen bei Abgabe des Artikels ein formloses COI-Statement abgeben, das mit abgedruckt wird. Es gibt hierzu keine Vorlage des Verlags.
2. **Submission Statement:** Es muss für jedes Manuskript von allen Autoren unterzeichnet werden. Bitte fügen Sie jeweils den Titel oben ein, damit die Unterschriften dem richtigen Manuskript zuzuordnen sind. Autoren, die bei beiden Manuskripten auf der Liste stehen, müssen auch **zweimal** unterschreiben.

**Deadline-Erweiterung bis 24.03.2019**

Viele Grüße von Marc und Nina

Submission Statement direkt  
an Verlag



## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name)  
Christian

2. Surname (Last Name)  
Jackisch

3. Date  
25-March-2019

4. Are you the corresponding author?

Yes  No

Corresponding Author's Name

5. Manuscript Title

Chemotherapy and targeted drugs in metastatic breast cancer - AGO update 2019

6. Manuscript Identifying Number (if you know it)

### Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?  Yes  No

If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.

Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Roche	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
AstraZeneca	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Novartis	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest?  Yes  No

### Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  Yes  No



## ICMJE Form for Disclosure of Potential Conflicts of Interest

---

### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
- No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

### Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Jackisch reports personal fees from Roche, personal fees from AstraZeneca, personal fees from Novartis, during the conduct of the study; .

### Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.

Klinikum Esslingen GmbH · Postfach 10 07 53 · 73707 Esslingen

**Klinik Frauenheilkunde und Geburtshilfe**  
Chefarzt: Professor Dr. Thorsten Kühn

Interdisziplinäres Brustkrebszentrum  
Zentrum für gynäkologische Tumorerkrankungen  
Mutter-Kind-Zentrum  
Perinatalzentrum - Level 1

Tel. 0711 - 3103 3051

Fax 0711 - 3103 3052

frauenklinik@klinikum-esslingen.de

www.klinikum-esslingen.de


21.03.2019

## Erklärung über Interessenskonflikte für Zeitschrift „Breast Care“ ; Publikation der AGO Leitlinien



Hiermit erkläre ich, daß ich in Zusammenhang mit dem Kapitel operative Therapie unter onkologischen Aspekten keine themenspezifischen Interessenskonflikte habe.

Im Jahr 2018 habe ich Vertragshonorare der Firmen Pfizer, Celgene, Novartis und Roche Pharma erhalten.

  
Prof. Dr. med. T. Kühn  
Chefarzt

COI-Statement Breast Care publication 2019

## AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast\_Cancer: Update 2019,

### Specific Site of Metastases


Co-author

Ute-Susann Albert, Klinikum Kassel GmbH, Department of Gynecology and Obstetrics, Head of Senology and conservative Gyn-oncology, Medical School,, Mönchebergstr. 41-43, 34125 Kassel, Germany

COI-Statement:

I have been involved in advisory and review boards the last 5 years of the German health care federation (G-BA, IQTIG), for expert opinion and lectures I received financial reimbursement (< 5.000Euro) from Medexo GmbH, Institut für Versicherungsmedizin (IMV), Pfizer, Deutsche Gesellschaft für Verbrennungsmedizin, DRK-Krankenhaus Berlin. These disclosures I have been made before participating in the guideline process.

2019 March 19th, Kassel Prof. Ute-Susann Albert





**Klinikum Landshut gemeinnützige GmbH**  
Frauenklinik  
Chefarzt: Dr. med. Ingo Bauerfeind  
Gynäkologie - Geburtshilfe  
Brustkrebszentrum (DKG u. DIN EN ISO zertifiziert)  
Schwerpunkt gynäkologische Onkologie



Akademisches Lehrkrankenhaus der  
Ludwig-Maximilians-Universität München

Klinikum Landshut, Frauenklinik, Robert-Koch-Str. 1, 84034 Landshut

Fernruf: (0871) 698-3219  
Telefax: (0871) 698-3464  
E-Mail: [frauenklinik@klinikum-landshut.de](mailto:frauenklinik@klinikum-landshut.de)  
Internet: [www.klinikum-landshut.de](http://www.klinikum-landshut.de)  
Zeichen:  
Datum: 20.03.2019

Interessenkonflikte

Für den von mir bearbeiteten Abschnitt zum duktalem Carcinoma in situ habe ich keine Interessenkonflikte.

Mit freundlichen Grüßen

*Submission Statement  
an Verlag direkt gefaxt.*

Klinikum Landshut gemeinnützige GmbH  
Geschäftsführer: Dr. med. Philipp Ostwald  
Bankverbindung: Sparkasse Landshut  
VR Bank Landshut

Sitz der Gesellschaft: Landshut  
Aufsichtsratsvorsitzender: Alexander Putz  
DE 96 7435 0000 0004 1811 31  
DE 12 7439 0000 0001 4007 62

Amtsgericht Landshut, HRB 6171  
Steuer-Nr. 132/147/00500  
BIC: BYLADEM1LAH  
BIC: GENODEF1LH1

**Submission Statement**

**Article Title:**

Breast cancer risk and prevention

Every author must sign 1 copy of this Submission Statement with his/her original signature.

In signing the Submission Statement, the authors confirm that they have read and agreed to the full submission statement below, including that

- the submission is original and has not been previously published
- all permissions have been obtained
- the manuscript includes all the relevant statements and acknowledgements
- the copyright is transferred to S. Karger AG on acceptance

Printed Name:	E-Mail:	Signature:	Place and Date:
Ditsch, Nina	nina.ditsch @med.uni- muenchen.de	N. Ditsch	22.3.19 Munich

Please print and sign the form, and upload it during submission or fax or e-mail it to:

**S. Karger AG - Medical and Scientific Publishers**  
 Editorial Office *Breast Care*  
 Allschwilerstrasse 10  
 CH-4009 Basel (Switzerland)  
 Fax: +41 61 306 14 34  
 E-Mail: brc@karger.com

COI: MSD, Roche, AstraZeneca, ~~Amgen~~ TEVA

**Submission Statement**

Article Title:

B3 lesions

Every author must sign 1 copy of this Submission Statement with his/her original signature.

In signing the Submission Statement, the authors confirm that they have read and agreed to the full submission statement below, including that

- the submission is original and has not been previously published
- all permissions have been obtained
- the manuscript includes all the relevant statements and acknowledgements
- the copyright is transferred to S. Karger AG on acceptance

Printed Name:	E-Mail:	Signature:	Place and Date:
Ditsch, Nina	nina.ditsch @med.uni- muenchen.de	<i>N. Ditsch</i>	22.3.19 <i>Munich</i>

Please print and sign the form, and upload it during submission or fax or e-mail it to:

**S. Karger AG - Medical and Scientific Publishers**  
 Editorial Office *Breast Care*  
 Allschwilerstrasse 10  
 CH-4009 Basel (Switzerland)  
 Fax: +41 61 306 14 34  
 E-Mail: brc@karger.com

CO2: Roche, MSD, TEVA, AstraZeneca



## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

#### 1. Identifying information.

#### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



# ICMJE

INTERNATIONAL COMMITTEE of  
MEDICAL JOURNAL EDITORS

## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name)  
Peter

2. Surname (Last Name)  
Fasching

3. Date  
24-March-2019

4. Are you the corresponding author?

Yes  No

Corresponding Author's Name  
Ditsch und Thill

5. Manuscript Title  
AGO Recommendations 2019

6. Manuscript Identifying Number (if you know it)

### Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?  Yes  No

If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.

Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Novartis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Biontech	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Novartis	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Roche	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Pfizer	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Celgene	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Daiichi-Sankyo	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
TEVA	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Astra Zeneca	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Merck Sharp & Dohme	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Myelo Therapeutics	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Macrogenics	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Eisai	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Puma	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	



## ICMJE Form for Disclosure of Potential Conflicts of Interest

Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Cepheid	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest?  Yes  No

### Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  Yes  No

### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
- No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

### Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Fasching reports grants from Novartis, grants from Biontech, personal fees from Novartis, personal fees from Roche, personal fees from Pfizer, personal fees from Celgene, personal fees from Daiichi-Sankyo, personal fees from TEVA, personal fees from Astra Zeneca, personal fees from Merck Sharp & Dohme, personal fees from Myelo Therapeutics, personal fees from MacroGenics, personal fees from Eisai, personal fees from Puma, grants from Cepheid, during the conduct of the study; .

**Ditsch, Nina Prof. Dr.**

---

**Von:** Tanja.Fehm@med.uni-duesseldorf.de  
**Gesendet:** Sonntag, 24. März 2019 12:09  
**An:** Ditsch, Nina Prof. Dr.  
**Betreff:** WG:  
**Anlagen:** doc03369320190324120716.pdf

COIS:  
Amgen , Novartis, Pfizer, Roche, AstraZeneca, Lilly, Daichii Sankyo

-----Ursprüngliche Nachricht-----

Von: Scanner  
Gesendet: Sonntag, 24. März 2019 12:07  
An: Fehm, Prof. Dr. Tanja  
Betreff:

-----  
TA04769  
-----

**Ditsch, Nina Prof. Dr.**

---

**Von:** Friedrich, Michael <michael.friedrich@helios-gesundheit.de>  
**Gesendet:** Mittwoch, 20. März 2019 18:24  
**An:** Ditsch, Nina Prof. Dr.  
**Betreff:** AW: Breast Care: AGO Update 2019  
**Anlagen:** Brest\_Care\_20\_03\_19\_18\_07\_03.pdf

Liebe Nina, lieber Marc, anbei Submission Statement. Den Beitrag habe ich redigiert ist aber noch bei Sherko zur Korrektur. COI: Roche, Pfizer, AstraZeneca, Novartis

Beste Grüße

Euer Michael

---

**Von:** Ditsch, Nina Prof. Dr. [mailto:Nina.Ditsch@med.uni-muenchen.de]  
**Gesendet:** Mittwoch, 20. März 2019 09:45  
**An:** ago.mamma@lists.uni-ulm.de  
**Cc:** Marc.Thill@fdk.info  
**Betreff:** [EXTERN] Breast Care: AGO Update 2019

Liebe Autoren,

wir bedanken uns für die bereits zugesandten Artikel und bitten diejenigen, deren Artikel noch ausstehen, diese zu schicken – **bitte bis spätestens Sonntag Abend!!!**

Zusätzlich bitte an COI und Submission Statement denken (beides bitte mitschicken!!!)

1. **COI:** Alle Autoren müssen bei Abgabe des Artikels ein formloses COI-Statement abgeben, das mit abgedruckt wird. Es gibt hierzu keine Vorlage des Verlags.
2. **Submission Statement:** Es muss für jedes Manuskript von allen Autoren unterzeichnet werden. Bitte fügen Sie jeweils den Titel oben ein, damit die Unterschriften dem richtigen Manuskript zuzuordnen sind. Autoren, die bei beiden Manuskripten auf der Liste stehen, müssen auch **zweimal** unterschreiben.

**Deadline-Erweiterung bis 24.03.2019**

Viele Grüße von Marc und Nina



**AGO Breast Care Artikel:**

Potential conflicts of interests Prof. Dr. Nadia Harbeck

Honoraria for lectures and/or consulting: Agendia, Amgen, Astra Zeneca, Celgene, Daiichi-Sankyo, Genomic Health, Lilly, MSD, Nanostring, Novartis, Odonate, Pfizer, Roche, Sandoz/Hexal, Seattle Genetics

Prof. Dr. med. Wilfried Budach has received honoraria for Advisory Board activities and/or oral presentations from

- MSD
- Merck
- Pfizer
- BMS
- Bayer
- Novocure
- Nanobiotix

**Conflict of interest statement:**

Nicolai Maass received speakers honoraria from Roche Pharma.

Peter Sinn received research funding from Roche Pharma.

nachstehend meine COI-Angaben:

1. **Honoraria paid to my institution:** AbbVie, Amgen, AstraZeneca, Celgene, Novartis, Pfizer, Roche, Seattle Genetics, Teva, Vifor, PRIME, Daiichi.
2. **Research Institution:** GBG.
3. **Research grants paid to my institution:** AbbVie, Amgen, AstraZeneca, Celgene, Novartis, Pfizer, Roche, Teva, Vifor, Cepheid, NSABP, ABGSG, BIG, Myriad.
4. **Leadership roles:** GBG chair, BIG EB, ESMO Breast conference chair

Beste Grüße

Sibylle Loibl

\*\*\*\*\*

Prof. Dr. med. Sibylle Loibl

Chair of the German Breast Group

Prof. (apl) Goethe University Frankfurt/M

Clinical Consultant Centre for Haematology and Oncology/Bethanien Frankfurt/M

Chief Executive Officer

.....

**Conflict of Interest**

**Name:** Prof. Dr. Jens-Uwe Blohmer

**Article:** AGO Publikation BreastCare

**Date:** 24. 4. 2019

**Employment**

No Relationships to Disclose

**Leadership**

No Relationships to Disclose

**Stock and Other Ownership Interests**

No Relationships to Disclose

**Honoraria**

**Company:** Amgen

**Recipient:** Jens-Uwe Blohmer

**Company:** AstraZeneca

**Recipient:** Jens-Uwe Blohmer

**Company:** Genomic Health

**Recipient:** Jens-Uwe Blohmer

**Company:** MSD Oncology

**Recipient:** Jens-Uwe Blohmer

**Company:** Myriad Genetics

**Recipient:** Jens-Uwe Blohmer

**Company:** Novartis/Pfizer

**Recipient:** Jens-Uwe Blohmer

**Company:** Pfizer

**Recipient:** Jens-Uwe Blohmer

**Company:** Roche

**Recipient:** Jens-Uwe Blohmer

**Company:** Sonoscape

**Recipient:** Jens-Uwe Blohmer

